Marks Group Wealth Management Inc grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,952 shares of the company’s stock after buying an additional 1,280 shares during the quarter. Marks Group Wealth Management Inc’s holdings in AstraZeneca were worth $2,945,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Stratos Wealth Advisors LLC boosted its holdings in AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares during the last quarter. Crumly & Associates Inc. lifted its position in shares of AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after acquiring an additional 143 shares in the last quarter. Diversify Wealth Management LLC boosted its stake in shares of AstraZeneca by 3.6% in the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after acquiring an additional 153 shares during the last quarter. Veery Capital LLC increased its position in shares of AstraZeneca by 4.7% during the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock worth $230,000 after purchasing an additional 157 shares in the last quarter. Finally, Harbour Investments Inc. raised its stake in AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after purchasing an additional 160 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Trading Up 0.1 %
Shares of AZN stock opened at $72.73 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company’s 50-day moving average price is $67.58 and its 200-day moving average price is $73.52. The stock has a market cap of $225.54 billion, a price-to-earnings ratio of 32.18, a PEG ratio of 1.20 and a beta of 0.46.
AstraZeneca Increases Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be given a $1.03 dividend. This represents a yield of 2%. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date is Friday, February 21st. AstraZeneca’s dividend payout ratio is presently 43.36%.
Analyst Upgrades and Downgrades
AZN has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Morgan Stanley began coverage on shares of AstraZeneca in a research report on Wednesday. They set an “overweight” rating on the stock. Finally, UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $89.75.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Dividend Payout Ratio Calculator
- The Fast and the Casual: Is Taco Bell Catching Up to Chipotle?
- 3 Tickers Leading a Meme Stock Revival
- Broadcom Stock: Why the Upside Is Too Good to Ignore
- Upcoming IPO Stock Lockup Period, Explained
- Citigroup Analysts Are Betting Big on These 3 Stocks—Should You?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.